Consolidated Statements of Cash Flows - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Cash flows from operating activities:
Net (loss) income	$ (535.6)	$ 3,619.6	$ 3,322.0
Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:
Stock-based compensation expense	698.5	581.2	491.3
Depreciation and amortization expenses	207.2	181.3	148.3
Deferred income taxes	(348.8)	(536.5)	(275.9)
Losses on equity securities	57.7	0.6	149.1
Decrease in fair value of contingent consideration	(0.5)	(51.6)	(57.5)
Other non-cash items, net	(56.3)	8.4	11.8
Changes in operating assets and liabilities:
Accounts receivable, net	(99.3)	(84.1)	(358.6)
Inventories	(517.3)	(322.9)	(136.4)
Prepaid expenses and other assets	(200.3)	(545.7)	(326.4)
Accounts payable	49.5	48.7	120.8
Accrued expenses	212.9	429.4	542.5
Other liabilities	39.7	208.9	498.9
Net cash (used in) provided by operating activities	(492.6)	3,537.3	4,129.9
Cash flows from investing activities:
Purchases of available-for-sale debt securities	(7,438.2)	(3,786.5)	(692.7)
Sales and maturities of available-for-sale debt securities	4,465.6	839.1	920.0
Purchases of property and equipment	(297.7)	(200.4)	(204.7)
Sale of equity securities	0.0	95.1	0.0
Net payments related to finite-lived intangible assets	(187.7)	(58.0)	0.0
Acquisition of available-for-sale debt securities from Alpine Immune Sciences, Inc.	(258.0)	0.0	0.0
Payment to acquire ViaCyte, Inc., net of cash acquired	0.0	0.0	(295.9)
Other investing activities	(54.0)	(31.0)	(47.8)
Net cash used in investing activities	(3,770.0)	(3,141.7)	(321.1)
Cash flows from financing activities:
Issuances of common stock under benefit plans	114.6	134.6	186.3
Repurchases of common stock	(1,177.1)	(427.6)	0.0
Payments in connection with common stock withheld for employee tax obligations	(405.0)	(226.1)	(172.0)
Payments on finance leases	(33.6)	(44.9)	(85.5)
Other financing activities	6.2	1.8	3.5
Net cash used in financing activities	(1,494.9)	(562.2)	(67.7)
Effect of changes in exchange rates on cash	(42.6)	26.9	(29.2)
Net (decrease) increase in cash, cash equivalents and restricted cash	(5,800.1)	(139.7)	3,711.9
Cash, cash equivalents and restricted cash—beginning of period	10,372.3	10,512.0	6,800.1
Cash, cash equivalents and restricted cash—end of period	4,572.2	10,372.3	10,512.0
Supplemental disclosure of cash flow information:
Cash paid for income taxes	1,082.1	1,677.3	1,057.8
Cash paid for interest	30.5	43.1	52.3
Net payments due to CRISPR Therapeutics AG related to finite-lived intangible assets	$ 0.0	$ 180.0	$ 0.0